Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s
Webinar

Keynote webinar | Spotlight on advances in lupus

LIVE: Tuesday 27th May 2025, 18:00-19:15 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology

13-11-2024 | Ovarian Cancer | RESEARCH ARTICLE

Decoding β-catenin expression patterns in ovarian serous carcinoma with clinicopathological implications: insights from National Cancer Institute

Authors: Noura A. A. Ebrahim, Amany A. Abou-Bakr, Hassan N Tawfik, Hanan R. Nassar, Iman Adel

Published in: Clinical and Translational Oncology

Login to get access

Abstract

Aim

This study aimed to examine the immunohistochemical expression of β-catenin in serous ovarian carcinoma and to investigate its relationship with clinicopathological features and disease outcomes.

Methods

A retrospective analysis was conducted on 67 cases of serous ovarian carcinoma diagnosed at the Pathology Department of the Egyptian National Cancer Institute, Cairo University, between January 1, 2015, and December 31, 2017.

Results

The age of the patients ranged from 26 to 76 years. Aberrant β-catenin expression was defined by the presence of cytoplasmic staining with or without membranous staining in at least 10% of tumor cells. Of the cases analyzed, thirty exhibited cytoplasmic staining, 18 demonstrated preserved expression on the cell membrane, 15 showed combined cytoplasmic and membranous staining, while four cases were entirely negative. Significant correlations were observed between β-catenin positivity and both tumor grade and p53 expression, with p values of 0.004 for each correlation.

Conclusions

Positive β-catenin expression significantly correlated with tumor grade in serous ovarian carcinoma. Most low-grade serous carcinoma cases exhibited membranous β-catenin expression, whereas high-grade serous carcinoma cases predominantly displayed cytoplasmic staining. Therapeutic strategies aimed at inhibiting β-catenin signaling could provide a novel approach to improving outcomes for patients with high-grade ovarian cancer.

Graphical abstract

Literature
1.
2.
3.
Rastegar-Pouyani N, Montazeri V, Marandi N, Aliebrahimi S, Andalib M, Jafarzadeh E, Ostad SN. The impact of cancer-associated fibroblasts on drug resistance, stemness, and epithelial-mesenchymal transition in bladder cancer: a comparison between recurrent and non-recurrent patient-derived CAFs. Cancer Investig. 2023;41(7):656–71.CrossRef
4.
Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Women’s Health. 2019;11:287–99.CrossRef
5.
Zamwar UM, Anjankar AP. Aetiology, epidemiology, histopathology, classification, detailed evaluation, and treatment of ovarian cancer. Cureus. 2022;14(10): e30561.PubMedPubMedCentral
6.
Yuichiro H, Kayoko H, Maho T, Ken-ichirou M, Hiroyuki T, Hiroyuki Y, et al. A comprehensive review of ovarian serous carcinoma. Adv Anat Pathol. 2019; 26(5):329–39.
7.
8.
9.
Nguyen VHL, Hough R, Bernaudo S, Peng C. Wnt/β-catenin signalling in ovarian cancer: insights into its hyperactivation and function in tumorigenesis. J Ovarian Res. 2019;12(1):122.CrossRefPubMedPubMedCentral
10.
Koyama K, Maeda D, Kito M, Tamura D, Kudo-Asabe Y, Ishikawa S, et al. Clinicopathological and molecular analyses of linearly expanded epithelial cells with β-catenin alterations, “β-catenin signature,” in the normal fallopian tube. Histopathology. 2020;77(6):880–9.CrossRefPubMed
11.
Bodnar L, Stanczak A, Cierniak S, Smoter M, Cichowicz M, Kozlowski W, et al. Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. J Ovarian Res. 2014;7:16.CrossRefPubMedPubMedCentral
12.
Caviglia JM, Schwabe RF. Experimental hepatocarcinogenesis. In: McManus LM, Mitchell RN, editors. Pathobiology of human disease. New York: Academic Press; 2014. p. 1866–80.CrossRef
13.
14.
15.
Tauriello DV, Jordens I, Kirchner K, Slootstra JW, Kruitwagen T, Bouwman BA, et al. Wnt/β-catenin signaling requires interaction of the Dishevelled DEP domain and C terminus with a discontinuous motif in Frizzled. Proc Natl Acad Sci USA. 2012;109(14):E812–20.CrossRefPubMedPubMedCentral
16.
Angelico G, Ieni A, Caltabiano R, Santoro A, Inzani F, Spadola S, et al. Evaluation of beta-catenin subcellular localization and water channel protein AQP1 expression as predictive markers of chemo-resistance in ovarian high-grade serous carcinoma: comparative study between reoperative peritoneal biopsies and surgical samples. Diagnostics. 2021;11:452.CrossRefPubMedPubMedCentral
17.
Köbel M, Kang EY. The many uses of p53 immunohistochemistry in gynecological pathology: Proceedings of the ISGyP Companion Society session at the 2020 USCAP annual meeting. Int J Gynecol Pathol. 2021;40(1):32–40.CrossRefPubMed
18.
Ghosh T, Sarkar P, Chakraborty B, Guha D, Bal R. A study of β-catenin and PTEN expression in ovarian surface epithelial neoplasms and their correlation with grade and stage in malignant cases. Int J Contemp Med Res. 2019;6(3):C8–15.
19.
Zannoni GF, Angelico G, Santoro A. Aberrant non-canonical WNT pathway as keydriver of high-grade serous ovarian cancer development. Virchows Arch. 2020;477(2):321–2.CrossRefPubMed
20.
Mahomed F, Altini M, Meer S. Altered E-cadherin/β-catenin expression in oral squamous carcinoma with and without nodal metastasis. Oral Dis. 2007;13:386–92.CrossRefPubMed
Metadata
Title
Decoding β-catenin expression patterns in ovarian serous carcinoma with clinicopathological implications: insights from National Cancer Institute
Authors
Noura A. A. Ebrahim
Amany A. Abou-Bakr
Hassan N Tawfik
Hanan R. Nassar
Iman Adel
Publication date
13-11-2024
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-024-03770-4

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Video
Image Credits